Beacon Biosignals has unveiled groundbreaking findings that bolster the efficacy of its EEG headband for sleep analysis. Based in Boston, the company developed the Dreem 3S headband, equipped with machine-learning capabilities. This sophisticated wearable includes six electrodes and an inbuilt accelerometer to track head and body movements, collecting EEG data to analyze sleep patterns and aid in identifying sleep disturbances.
The system achieved FDA approval in September 2023, with additional clearances for enhanced algorithms granted earlier this month.
Beacon Biosignals emphasizes that its user-friendly device simplifies the process for patients to engage in clinically proven EEG-based sleep assessments. By leveraging it in the comfort of their homes, users can gain new insights into their sleep physiology. The Dreem 3S stands out as the pioneering dry-EEG healthcare device designed for home use, facilitating easy data collection without professional supervision. It offers users the capability to independently conduct recordings that span a full day.
The company showcased two research posters during the American Epilepsy Society (AES) Annual Meeting this week, focusing on advancing knowledge of sleep disruptions in Lennox-Gastaut Syndrome (LGS) patients and their caregivers.
Novel Observations from Beacon Biosignals:
In collaboration with Longboard Pharmaceuticals, Beacon Biosignals shared early results from the Dreem LGS Caregiver Study, utilizing the Dreem 3S to delve into sleep disturbances experienced by caregivers of children with LGS.
The study revealed that caregivers efficiently operated the home-based EEG device over multiple nights without the need for technical assistance, capturing high-quality recordings. The data highlighted a considerable rise in wake after sleep onset (WASO) among LGS caregivers, at 37.79 minutes compared to 24.70 minutes in the control group, and a reduced time to fall asleep at 14.62 minutes versus 23.43 minutes in controls. According to Beacon Biosignals, these findings lay the groundwork for understanding the connection between caregiver stress, burden, and sleep quality within this unserved demographic.
The second poster, produced in partnership with UCB, centered on the HEADFIRST study. This research investigates sleep architecture among children with LGS and their neurotypical siblings. Through the use of Dreem 3S, distinct variations in sleep patterns were detected in LGS participants, including amplified WASO and diminished sleep cycles. Notably, LGS subjects exhibited prominent reductions in REM sleep, recording 56.77 minutes compared to 104.34 minutes in control subjects, consistent with the syndrome’s neurological basis.
Beacon Biosignals believes these outcomes are crucial for evaluating the Dreem 3S’s ability to address the limitations of traditional wired EEG systems.
“Our presentations at the AES highlight the revolutionary potential of Beacon’s technology in driving forward neurodiagnostics,” stated David Matthews, chief business officer at Beacon Biosignals. “By collaborating with industry pioneers such as UCB and Longboard, we are making significant strides in understanding epilepsy-related sleep disorders, fostering the creation of innovative treatments, and ultimately improving patient and family outcomes.”